FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225136075> ?p ?o ?g. }

• W4225136075 endingPage "941" @default.
• W4225136075 startingPage "933" @default.
• W4225136075 abstract "In this open-label, single-arm, phase I/II clinical trial, we evaluated the efficacy of anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) therapy in 49 relapsed/refractory multiple myeloma (RRMM) patients, including 20 with Eastern Cooperative Oncology Group (ECOG) grade 3-4. After HDS269B infusion (9 × 106 CAR+ cells/kg), 17 patients (34.69%, 11 ECOG 0-2, 6 ECOG 3-4) developed cytokine release syndrome [grade 1-2: 14 patients (28.57%); grade 3: 3 patients (6.12%)]. The objective response rate (ORR) was 77%, with a complete response (CR) achieved in 47%. Ongoing response >12 months occurred in 15 patients, and was extended beyond 38 months in one patient. The median progression-free survival (PFS) and overall survival (OS) were 10 months (95% CI 5.3-14.7) and 29 months (95% CI 10.0-48.0), respectively. The PFS (12 months) and OS (18 months) rates were 41.64% and 62.76%, respectively. In patients with ECOG 0-2 and 3-4, ORR was 79.31% (23/29) and 75.0% (15/20) and PFS were 15 months (95% CI 5.4-24.6) and 4 months (95% CI 0-11.7), respectively. OS was not reached in ECOG 0-2 patients, but was 10.5 months (95% CI 0-22) in ECOG 3-4 patients. Single-cell sequencing indicated that treatment efficacy might be related to mTORC1 signaling. Thus, HDS269B therapy is safe and effective for RRMM patients, even those with ECOG 3-4." @default.
• W4225136075 created "2022-05-01" @default.
• W4225136075 creator A5000993677 @default.
• W4225136075 creator A5001366115 @default.
• W4225136075 creator A5010428239 @default.
• W4225136075 creator A5012541451 @default.
• W4225136075 creator A5014135403 @default.
• W4225136075 creator A5017470979 @default.
• W4225136075 creator A5028349844 @default.
• W4225136075 creator A5039117319 @default.
• W4225136075 creator A5041245196 @default.
• W4225136075 creator A5043019475 @default.
• W4225136075 creator A5046001715 @default.
• W4225136075 creator A5049396819 @default.
• W4225136075 creator A5050247259 @default.
• W4225136075 creator A5056253982 @default.
• W4225136075 creator A5057872518 @default.
• W4225136075 creator A5069469021 @default.
• W4225136075 creator A5078772381 @default.
• W4225136075 date "2022-05-05" @default.
• W4225136075 modified "2023-10-16" @default.
• W4225136075 title "<scp>CAR‐T</scp> cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status" @default.
• W4225136075 cites W1988265934 @default.
• W4225136075 cites W2028133290 @default.
• W4225136075 cites W2035618305 @default.
• W4225136075 cites W2038477042 @default.
• W4225136075 cites W2041346873 @default.
• W4225136075 cites W2059581635 @default.
• W4225136075 cites W2082708772 @default.
• W4225136075 cites W2144728882 @default.
• W4225136075 cites W2151480449 @default.
• W4225136075 cites W2172557341 @default.
• W4225136075 cites W2191437528 @default.
• W4225136075 cites W2471662063 @default.
• W4225136075 cites W2512972788 @default.
• W4225136075 cites W2625253716 @default.
• W4225136075 cites W2755114342 @default.
• W4225136075 cites W2790173378 @default.
• W4225136075 cites W2807637103 @default.
• W4225136075 cites W2864786814 @default.
• W4225136075 cites W2883059111 @default.
• W4225136075 cites W2900366494 @default.
• W4225136075 cites W2901262057 @default.
• W4225136075 cites W2907514116 @default.
• W4225136075 cites W2921533600 @default.
• W4225136075 cites W2924578117 @default.
• W4225136075 cites W2938308258 @default.
• W4225136075 cites W2943335541 @default.
• W4225136075 cites W2969931905 @default.
• W4225136075 cites W2979807505 @default.
• W4225136075 cites W3089287956 @default.
• W4225136075 cites W3129464308 @default.
• W4225136075 cites W3137893730 @default.
• W4225136075 cites W4236730981 @default.
• W4225136075 cites W4376542883 @default.
• W4225136075 doi "https://doi.org/10.1002/ajh.26583" @default.
• W4225136075 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35488407" @default.
• W4225136075 hasPublicationYear "2022" @default.
• W4225136075 type Work @default.
• W4225136075 citedByCount "6" @default.
• W4225136075 countsByYear W42251360752022 @default.
• W4225136075 countsByYear W42251360752023 @default.
• W4225136075 crossrefType "journal-article" @default.
• W4225136075 hasAuthorship W4225136075A5000993677 @default.
• W4225136075 hasAuthorship W4225136075A5001366115 @default.
• W4225136075 hasAuthorship W4225136075A5010428239 @default.
• W4225136075 hasAuthorship W4225136075A5012541451 @default.
• W4225136075 hasAuthorship W4225136075A5014135403 @default.
• W4225136075 hasAuthorship W4225136075A5017470979 @default.
• W4225136075 hasAuthorship W4225136075A5028349844 @default.
• W4225136075 hasAuthorship W4225136075A5039117319 @default.
• W4225136075 hasAuthorship W4225136075A5041245196 @default.
• W4225136075 hasAuthorship W4225136075A5043019475 @default.
• W4225136075 hasAuthorship W4225136075A5046001715 @default.
• W4225136075 hasAuthorship W4225136075A5049396819 @default.
• W4225136075 hasAuthorship W4225136075A5050247259 @default.
• W4225136075 hasAuthorship W4225136075A5056253982 @default.
• W4225136075 hasAuthorship W4225136075A5057872518 @default.
• W4225136075 hasAuthorship W4225136075A5069469021 @default.
• W4225136075 hasAuthorship W4225136075A5078772381 @default.
• W4225136075 hasConcept C121332964 @default.
• W4225136075 hasConcept C121608353 @default.
• W4225136075 hasConcept C126322002 @default.
• W4225136075 hasConcept C142424586 @default.
• W4225136075 hasConcept C143998085 @default.
• W4225136075 hasConcept C147483822 @default.
• W4225136075 hasConcept C203014093 @default.
• W4225136075 hasConcept C2776364478 @default.
• W4225136075 hasConcept C2776694085 @default.
• W4225136075 hasConcept C2777701055 @default.
• W4225136075 hasConcept C2780739268 @default.
• W4225136075 hasConcept C2780850621 @default.
• W4225136075 hasConcept C3875195 @default.
• W4225136075 hasConcept C71924100 @default.
• W4225136075 hasConcept C87355193 @default.
• W4225136075 hasConcept C90924648 @default.
• W4225136075 hasConceptScore W4225136075C121332964 @default.
• W4225136075 hasConceptScore W4225136075C121608353 @default.

• next